1Libby P. Inflammation in atherosclerosis[J].NATURE,2002,(6917):868-874.doi:10.1038/nature01323.
2Aikawa M,Libby P. The vulnerable atherosclerotic plaque:pathogenesis and therapeutic approach[J].Cardiovascular Pathology,2004,(03):125-138.doi:10.1016/S1054-8807(04)00004-3.
3Libby P,Theroux P. Pathophysiology of coronary artery disease[J].Circulation,2005,(25).doi:10.1161/CIRCULATIONAHA.105.537878.
4Danesh J,Wheeler JG,Hirschfield GM. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J].New England Journal of Medicine,2004,(14):1387.doi:10.1056/NEJMoa032804.
5Porsch Qezmeruemez M,Kunz D,Hans Ulrich K. Evaluation of seturn levels of solubilized adhesion molecules an d cytokine receptors in coronary heart disease[J].Journal of the American College of Cardiology,1999.34.
6Ikata J,Wakatsuki T,Oishi Y. Leukocyte counts and concetration of soluble ashesion molecules as predictors of coronary atherogenesis[J].Coron ArteryDis,2000,(06):445.doi:10.1097/00019501-200009000-00001.
7Mach F,Schonbeck U,Sukhova GK. Reduction of atherosclerosis in mice by inhibition of CD40 signalling[J].Nature,1998.200-203.doi:10.1038/28204.
8Schonbeck U,Sukhova GK,Shimizu K. Inhibition of CIM0 signaling limits evolution of established atherosclerosis in mice[J].Proc Nad Aead Sci U S A,2000,(13):7458-7463.doi:10.1073/pnas.97.13.7458.
9Tsukamoto N,Kobayashi N,Azuma S. Two differenfly regulated NF-B activation pathway striggered by thecytoplasmic tail of CD40[J].Proceedings of the National Academy of Sciences(USA),1999,(4):1234-1239.doi:10.1073/pnas.96.4.1234.
10Lutgens E,Cleutjens KBJM,Heeneman S. Both early and delayedanti-CD40L antibody treatment induce sastable plaque phenotype[J].Proceedings of the National Academy of Sciences(USA),2000,(13):7464-7469.doi:10.1073/pnas.97.13.7464.
